STOCK TITAN
  1. Home
  2. Sec-filings
  3. MAIA
  4. [Form 4/A] MAIA Biotechnology, Inc. Amended Insider Trading Activity

MAIA Biotechnology (NASDAQ: MAIA) CEO Vlad Vitoc reports new insider share purchases

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

MAIA Biotechnology’s chief executive officer, director and 10% owner Vlad Vitoc reported open‑market purchases of the company’s common stock and corrected prior share balances. On November 26, 2025, he bought 22,000 shares at a weighted average price of $1.0463 per share, and on November 28, 2025 he bought an additional 50,000 shares at a weighted average price of $1.1366 per share. Following these transactions, he directly owns 903,421 shares of MAIA common stock and has indirect beneficial ownership of 210,100 shares held by his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest. This Form 4 amendment corrects the previously reported total share balances for both his holdings and his spouse’s holdings.

Positive

  • None.

Negative

  • None.
Insider Vitoc Vlad
Role Chief Executive Officer
Bought 72,000 shs ($80K)
Type Security Shares Price Value
Purchase Common Stock 50,000 $1.1366 $57K
Purchase Common Stock 22,000 $1.0463 $23K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 903,421 shares (Direct); Common Stock — 210,100 shares (Indirect, See Footnote)
Footnotes (1)
  1. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.0145 to $1.0587, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.1283 to $1.1416, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. The original Form 4 filed on December 1, 2025 had the incorrect total share balance owned by Vlad Vitoc. This Amended Form 4 is now reflecting the correct share balance owned. The original Form 4 filed on December 1, 2025 had the incorrect total share balance owned by Mr. Vitoc's spouse. This Amended Form 4 is now reflecting the correct share balance owned. These securities are beneficially owned by Mr. Vitoc's spouse. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Vitoc Vlad
(Last) (First) (Middle)
444 WEST LAKE STREET,
(Street)
CHICAGO IL 60606
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/26/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
12/01/2025 		6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/26/2025 P 22,000 A $1.0463(1) 853,421 D
Common Stock 11/28/2025 P 50,000 A $1.1366(2) 903,421(3) D
Common Stock 210,100(4) I See Footnote(5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.0145 to $1.0587, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
2. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.1283 to $1.1416, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
3. The original Form 4 filed on December 1, 2025 had the incorrect total share balance owned by Vlad Vitoc. This Amended Form 4 is now reflecting the correct share balance owned.
4. The original Form 4 filed on December 1, 2025 had the incorrect total share balance owned by Mr. Vitoc's spouse. This Amended Form 4 is now reflecting the correct share balance owned.
5. These securities are beneficially owned by Mr. Vitoc's spouse. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
/s/ Vlad Vitoc 12/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did MAIA (MAIA) disclose in this Form 4/A?

The filing reports that CEO, director and 10% owner Vlad Vitoc purchased 22,000 MAIA shares on November 26, 2025 at a weighted average price of $1.0463, and 50,000 shares on November 28, 2025 at a weighted average price of $1.1366.

How many MAIA (MAIA) shares does Vlad Vitoc own after the reported transactions?

After the reported purchases, Vlad Vitoc directly owns 903,421 shares of MAIA common stock and has indirect beneficial ownership of 210,100 shares held by his spouse.

Why was this MAIA (MAIA) Form 4/A filed as an amendment?

The amendment states that the original Form 4 filed on December 1, 2025 reported an incorrect total share balance owned by Vlad Vitoc and an incorrect total share balance owned by his spouse, and this Form 4/A corrects those totals.

How were the purchase prices for MAIA (MAIA) shares calculated in the filing?

For both transactions, the reported prices are weighted average prices. On November 26, 2025, shares were bought in multiple trades between $1.0145 and $1.0587. On November 28, 2025, trades occurred between $1.1283 and $1.1416.

How does the filing describe Vlad Vitoc’s indirect ownership of MAIA (MAIA) shares?

The filing notes that 210,100 shares are beneficially owned by Mr. Vitoc’s spouse. He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest in them.

What is Vlad Vitoc’s role and relationship to MAIA (MAIA) according to the filing?

The reporting person is identified as a director, a 10% owner, and an officer of MAIA Biotechnology, Inc., serving as the company’s Chief Executive Officer.